Log in

NASDAQ:TSRX - Trius Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Trius Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:TSRX
CUSIP89685K10
Phone+1-781-8608660

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive TSRX News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRX and its competitors with MarketBeat's FREE daily newsletter.


Trius Therapeutics (NASDAQ:TSRX) Frequently Asked Questions

What is Trius Therapeutics' stock symbol?

Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX."

Has Trius Therapeutics been receiving favorable news coverage?

Media stories about TSRX stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trius Therapeutics earned a news impact score of -4.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Trius Therapeutics.

Who are some of Trius Therapeutics' key competitors?

What other stocks do shareholders of Trius Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trius Therapeutics investors own include Opko Health (OPK), Pharmacyclics (PCYC), InvenSense (INVN), Molycorp (MCPIQ), ACADIA Pharmaceuticals (ACAD), AcelRx Pharmaceuticals (ACRX), Alkermes (ALKS), Alnylam Pharmaceuticals (ALNY), Alexion Pharmaceuticals (ALXN) and Amarin (AMRN).

What is Trius Therapeutics' official website?

The official website for Trius Therapeutics is http://www.triusrx.com/.

How can I contact Trius Therapeutics?

Trius Therapeutics' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.


MarketBeat Community Rating for Trius Therapeutics (NASDAQ TSRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe TSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel